Sign In
Buy STTK
$4.75
-0.120 (-2.46%)
At Close: Jun 03, 2026
NEW YORK CITY, NY / ACCESSWIRE / October 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N
Shattuck Labs, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Shattuck Labs, Inc. (STTK)
04:30pm, Tuesday, 15'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possib
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. (“Shattuck”
STTK STOCK ALERT: Levi & Korsinsky Notifies Shattuck Labs, Inc. Investors of an Ongoing Investigation
11:30am, Tuesday, 15'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possib
NEW YORK CITY, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK
07:30pm, Monday, 14'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advis
Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation
06:00pm, Monday, 14'th Oct 2024
NEW YORK CITY, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N
After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
10:35am, Tuesday, 08'th Oct 2024
The heavy selling pressure might have exhausted for Shattuck Labs (STTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analy
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
11:25am, Wednesday, 02'nd Oct 2024
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial
12:23pm, Tuesday, 01'st Oct 2024
The stock hit a low of $1.37 earlier in the session, matching its record closing low that was set in October 2023.
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improv
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates
07:20pm, Thursday, 01'st Aug 2024
Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.50 per share a year ago.
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
05:00pm, Tuesday, 30'th Jul 2024
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
06:00am, Monday, 01'st Jul 2024
AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion prote
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
02:31pm, Friday, 14'th Jun 2024
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the pha
